Free Trial

Connect Biopharma (CNTB) Stock Price, News & Analysis

$1.25
-0.02 (-1.57%)
(As of 07/12/2024 ET)
Today's Range
$1.24
$1.31
50-Day Range
$1.24
$2.04
52-Week Range
$0.53
$2.84
Volume
9,527 shs
Average Volume
81,832 shs
Market Capitalization
$68.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Connect Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
420.0% Upside
$6.50 Price Target
Short Interest
Healthy
0.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.65mentions of Connect Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.54 to ($0.63) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.42 out of 5 stars

Medical Sector

287th out of 917 stocks

Pharmaceutical Preparations Industry

124th out of 435 stocks

CNTB stock logo

About Connect Biopharma Stock (NASDAQ:CNTB)

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

CNTB Stock Price History

CNTB Stock News Headlines

Musk’s new company could top a trillion?
The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.
Connect Biopharma Holdings Limited (CNTB)
Musk’s new company could top a trillion?
The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.
ADRs Advance; Connect Biopharma Climbs 19%
ADRs End Higher; Connect Biopharma Climbs 26%
See More Headlines
Receive CNTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
7/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNTB
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.50
High Stock Price Target
$8.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+420.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.83 per share

Miscellaneous

Free Float
42,650,000
Market Cap
$68.88 million
Optionable
Optionable
Beta
-0.39
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Wubin Pan M.B.A. (Age 59)
    Ph.D., Co-Founder, President & Chairman of the Board of Directors
  • Dr. Zheng Wei Ph.D. (Age 60)
    Co-Founder, CEO & Director
  • Mr. Steven Chan (Age 52)
    Chief Financial Officer
  • Mr. Jiang Bian J.D.
    General Counsel & Chief Compliance Officer
  • Dr. Lei Sun Ph.D. (Age 60)
    VP of Biologics & Head of CMC
  • Dr. Raul Collazo Ph.D.
    VP & Global Head of Medical Affairs
  • Dr. Malinda V. Longphre Ph.D.
    VP & Head of US Clinical Operations

CNTB Stock Analysis - Frequently Asked Questions

How have CNTB shares performed this year?

Connect Biopharma's stock was trading at $1.18 at the beginning of 2024. Since then, CNTB stock has increased by 5.9% and is now trading at $1.25.
View the best growth stocks for 2024 here
.

When did Connect Biopharma IPO?

Connect Biopharma (CNTB) raised $150 million in an initial public offering on Friday, March 19th 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO.

How do I buy shares of Connect Biopharma?

Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTB) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners